KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Treasury Shares (2019 - 2025)

Royalty Pharma's Treasury Shares history spans 7 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 1.88% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, down 1.88%, while the annual FY2025 figure was $2.6 million, 1.88% down from the prior year.
  • Treasury Shares for Q4 2025 was $19.5 million at Royalty Pharma, down from $20.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $21.5 million in Q2 2025 and bottomed at $3.1 million in Q2 2024.
  • The 3-year median for Treasury Shares is $8.4 million (2024), against an average of $10.9 million.
  • The largest annual shift saw Treasury Shares increased 25.63% in 2021 before it fell 6.31% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $2.7 million in 2021, then grew by 3.35% to $2.8 million in 2022, then fell by 6.31% to $2.6 million in 2023, then rose by 1.26% to $2.7 million in 2024, then decreased by 1.88% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Treasury Shares are $2.6 million (Q4 2025), $2.6 million (Q3 2025), and $2.6 million (Q2 2025).